1330766-08-9 Usage
Uses
Used in Organic Synthesis:
3-Boc-8-hydroxy-3-azabicyclo[3.2.1]octane is used as a key intermediate in the synthesis of complex organic molecules. Its Boc group serves as a protecting agent, which is crucial for preventing unwanted side reactions during the synthesis process.
Used in Pharmaceutical Development:
3-Boc-8-hydroxy-3-azabicyclo[3.2.1]octane is used as a building block in the development of new pharmaceutical compounds. The hydroxy functional group in the compound may be involved in the formation of hydrogen bonds, which is essential for the interaction of the compound with biological targets, such as enzymes or receptors.
Used in Chemical Research:
3-Boc-8-hydroxy-3-azabicyclo[3.2.1]octane is used as a model compound in chemical research to study the effects of the azabicyclo octane ring structure and the Boc protecting group on the reactivity and properties of the compound. This research can provide valuable insights into the design and synthesis of new organic compounds with specific chemical and biological properties.
Check Digit Verification of cas no
The CAS Registry Mumber 1330766-08-9 includes 10 digits separated into 3 groups by hyphens. The first part of the number,starting from the left, has 7 digits, 1,3,3,0,7,6 and 6 respectively; the second part has 2 digits, 0 and 8 respectively.
Calculate Digit Verification of CAS Registry Number 1330766-08:
(9*1)+(8*3)+(7*3)+(6*0)+(5*7)+(4*6)+(3*6)+(2*0)+(1*8)=139
139 % 10 = 9
So 1330766-08-9 is a valid CAS Registry Number.
1330766-08-9Relevant academic research and scientific papers
FXR RECEPTOR MODULATOR, PREPARATION METHOD THEREFOR, AND USES THEREOF
-
Paragraph 0072; 0075, (2018/11/27)
The present disclosure disclosed a modulator of FXR receptor and preparation and use thereof, which relates to the technical filed of medicinal chemistry. The present disclosure provides a modulator of FXR receptor having a structural formula I or a pharmaceutically acceptable salt, stereoisomer, solvate or prodrug thereof, which can combine with FXR receptor (that is NR1H4) and be acted as a FXR agonist or a partial agonist for preventing and treating the disease mediated by FXR, such as chronic intrahepatic or extrahepatic cholestasis, hepatic fibrosis caused by chronic cholestasis or acute intrahepatic cholestasis, chronic hepatitis B, gallstone, hepatic carcinoma, colon cancer or intestinal inflammatory disease, etc. Specifically, for some chemical compounds, their EC50 for FXR agonist activity reach below 100nM, which show an excellent FXR agonist activity and an excellent prospect to provide a new pharmaceutical selection in clinical treatment for the disease mediated by FXR.
